http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer's Disease at Alzheimer's Association International Conference (AAIC) 2018
-
Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018
-
Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018
-
Biogen (BIIB), Eisai Announce Detailed Results Of Phase II Clinical Study Of BAN2401 In Early Alzheimer's Disease
-
Eisai And Biogen Announce Detailed Results Of Phase II Clinical Study Of BAN2401 In Early Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018
-
Biogen (BIIB), Eisai Highlight Detailed Results from Phase II Clinical Study of Elenbecestat at AAIC 2018
-
Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer's Disease at Alzheimer's Association International Conference (AAIC) 2018
-
Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 20
-
Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 20
-
Eisai And Biogen Present Detailed Results From Phase II Clinical Study Of Elenbecestat In MCI And Mild To Moderate Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018
-
S&P reaches highest level since February as Alphabet shares soar
-
Biogen to Host Investor Webcast to Discuss Alzheimer’s Disease Portfolio on July 25, 2018
-
Biogen to Host Investor Webcast to Discuss Alzheimer’s Disease Portfolio on July 25, 2018
-
Data to be Presented From Biogen's Alzheimer's Disease Clinical Development Portfolio at the 2018 Alzheimer's Association International Conference (AAIC)
-
Data to be Presented From Biogen’s Alzheimer’s Disease Clinical Development Portfolio at the 2018 Alzheimer’s Association International Conference (AAIC)
-
Data to be Presented From Biogen’s Alzheimer’s Disease Clinical Development Portfolio at the 2018 Alzheimer’s Association International Conference (AAIC)
-
Biogen (BIIB), Eisai Co. Ltd. Report Positive Topline Results of the Final Analysis For BAN2401 at 18 Months
-
Eisai And Biogen Announce Positive Topline Results Of The Final Analysis For BAN2401 At 18 Months
-
Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months
-
Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months
-
Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months
-
Biogen (BIIB) to Pay $700 Million to Increase Stake in Samsung Bioepis to 49.9%
-
Biogen Exercises Option to Increase Ownership in Samsung Bioepis
-
Biogen Exercises Option to Increase Ownership in Samsung Bioepis
-
Biogen Exercises Option to Increase Ownership in Samsung Bioepis
-
Biogen to Report Second Quarter 2018 Financial Results on July 24, 2018
-
Biogen to Report Second Quarter 2018 Financial Results on July 24, 2018
-
Biogen to Host Investor Webcast on Its Efforts Targeting Stroke on June 28, 2018
-
Biogen to Host Investor Webcast on Its Efforts Targeting Stroke on June 28, 2018
-
Biogen (BIIB) & Samsung Bioepis Co. Report Joint Analysis Results of Anti-TNF Biosimilars BENEPALI (etanercept), FLIXABI (infliximab) & IMRALDI (adalimumab) at EULAR 2018
-
Samsung Bioepis and Biogen Announce Pooled Analysis Results of Anti-TNF Biosimilars BENEPALI™ (etanercept), FLIXABI™ (infliximab), and IMRALDI™ (adalimumab) at EULAR 2018
-
Biogen Enhances Commitment to SMA Research with Data Presented at Annual SMA Conference
-
Biogen Enhances Commitment to SMA Research with Data Presented at Annual SMA Conference
-
Biogen Enhances Commitment to SMA Research with Data Presented at Annual SMA Conference
-
Biogen (BIIB) to Acquire Acute Stroke Asset from TMS Co., Ltd. for $4M Upfront
-
Biogen (BIIB) Enters Exclusive Option Agreement to buy TMS' Phase 2 Asset for Acute Stroke
-
Biogen Enters Exclusive Option Agreement to Acquire TMS' Phase 2 Asset for Acute Stroke
-
Biogen Enters Exclusive Option Agreement to Acquire TMS’ Phase 2 Asset for Acute Stroke
-
Biogen Enters Exclusive Option Agreement to Acquire TMS’ Phase 2 Asset for Acute Stroke
-
Eisai, Biogen (BIIB) Report Phase II Study Of Elenbecestat Demonstrated Safety And Tolerability In MCI And Mild To Moderate AD At 18-Months
-
Phase II Clinical Study Of Elenbecestat Demonstrates Safety And Tolerability In MCI And Mild To Moderate Alzheimer's Disease At 18-Months
-
Biogen Appoints Daniel Karp as EVP, Corporate Development
-
Biogen Appoints Daniel Karp as EVP, Corporate Development
-
Biogen Appoints Daniel Karp as EVP, Corporate Development
-
Biogen Celebrates 40 Years as a Pioneer in Neuroscience
-
Biogen (BIIB), Neurimmune Announce Option Exercise for Alzheimer’s Disease Investigational Treatment Aducanumab
-
Biogen and Neurimmune Announce Option Exercise for Alzheimer’s Disease Investigational Treatment Aducanumab
-
Biogen Reports Quarterly Revenues of $3.1 Billion
-
Biogen (BIIB) Reports New SPINRAZA (nusinersen) Data at AAN Meetings
-
New SPINRAZA® (nusinersen) Data Unveiled at AAN Annual Meeting Show Continued Improvement in Motor Function for Broad Age Range and Survival Benefit for Infants
